

General information about company

Scrip code*	000000			
NSE Symbol*	AAKAAR			
MSEI Symbol*	NOTLISTED			
ISIN*	INE1GYP01013			
Name of company	AAKAAR MEDICAL TECHNOLOGIES LIMITED			
Type of company	SME			
Class of security	Equity			
Date of start of financial year	01	04	2025	
Date of end of financial year	31	03	2026	
Date of board meeting when results were approved	15	05	2026	
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	01	04	2026	
Description of presentation currency	INR			
Level of rounding	Lakhs			
Reporting Type	Half Yearly			
Reporting Quarter	Yearly			
Nature of report standalone or consolidated	Standalone			
Whether results are audited or unaudited for the quarter ended	Audited	For Current Quarter Only		
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited			
Segment Reporting	Multi segment			
Description of single segment				
Start date and time of board meeting	15-05-2026	15	35	HH:MM
End date and time of board meeting	15-05-2026	16	00	HH:MM
Whether cash flow statement is applicable on company	Yes			
Type of cash flow statement	Cash Flow Indirect			
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion			
Whether the company has any related party?	Yes			
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes			
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA			
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA			
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No			
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?				
(b) If answer to above question is No, please explain the reason for not complying.				
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	Yes			
Latest Date on which RPT policy is updated	19-12-2024			
Indicate Company website link for updated RPT policy of the Company	www.aakaarmedical.in			
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	Yes			
No. of times funds raised during the quarter	1			
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No	Add Notes		

Financial Results – Other than Bank

Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-10-2025	01-04-2025
Date of end of reporting period		31-03-2026	31-03-2026
Whether results are audited or unaudited		Audited	Audited
Nature of report standalone or consolidated		Standalone	Standalone
Part I	Blue color marked fields are non-mandatory.		For
	Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
1	Revenue From Operations		
	Revenue from operations	4163.92	6696.41
	Other income	63.48	80.44
	Total Income	4227.40	6776.85
2	Expenses		
(a)	Cost of materials consumed	238.17	440.98
(b)	Purchases of stock-in-trade	1501.79	2899.13
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-63.90	-519.61
(d)	Employee benefit expense	674.68	1401.08
(e)	Finance costs	75.54	179.61
(f)	Depreciation and amortisation expense	7.92	12.83
(g)	Other Expenses		
1	Other Expenses	771.69	1443.65
2			
3			
4			
5			
6			
7			
8			
9			
10			
	Total other expenses	771.69	1443.65
	Total expenses	3205.89	5857.67
3	Profit before exceptional and extraordinary items and tax	1021.51	919.18
4	Exceptional items	0.00	0.00
5	Profit before extraordinary items and tax	1021.51	919.18
6	Extraordinary items	0.00	0.00
7	Profit before tax	1021.51	919.18
8	Tax Expense		
	Current tax	281.34	262.80
	Deferred tax	-1.99	-7.38
	Total tax expenses	279.35	255.42
9	Net Profit Loss for the period from continuing operations	742.16	663.76
10	Profit (loss) from discontinuing operations before tax	0.00	0.00
11	Tax expense of discontinuing operations	0.00	0.00
12	Net profit (loss) from discontinuing operation after tax	0.00	0.00
13	Profit (loss) for period before minority interest	742.16	663.76
14	Share of profit (loss) of associates		
15	Profit (loss) of minority interest		
16	Net profit (Loss) for the period	742.16	663.76
17	Details of equity share capital		
	Paid-up equity share capital	1417.28	1417.28
	Face value of equity share capital	10.00	10.00
18	Reserves excluding revaluation reserve		4037.78
19	Earnings per equity share (for continuing and discontinued operations)		
	Basic earnings (loss) per share from continuing and discontinued operations	5.24	4.99
	Diluted earnings (loss) per share from continuing and discontinued operations	5.24	4.99
20	Debt equity ratio	0.34	0.34
21	Debt service coverage ratio	11.39	4.09
22	Interest service coverage ratio	16.51	6.56
23	Disclosure of notes on financial results	Add Notes	

Home

Validate

Amount in (Lakhs)

Cash flow statement - indirect		
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2025
Date of end of reporting period		31-03-2026
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Standalone
1 Statement of cash flows		
Cash flows from used in operating activities		
Profit before extraordinary items and tax		919.18
2 Adjustments for reconcile profit (loss)		
Adjustments to profit (loss)		
Adjustments for finance costs		165.45
Adjustments for depreciation and amortisation expense		12.83
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss		0.00
Adjustments for unrealised foreign exchange losses gains		-1.51
Adjustments for dividend income		0.00
Adjustments for share-based payments		0.00
Other adjustments for which cash effects are investing or financing cash flow		0
Other adjustments to reconcile profit (loss)		30.42
Other adjustments for non-cash items		0.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships		0.00
Total adjustments to profit (loss)		207.19
3 Adjustments for working capital		
Adjustments for decrease (increase) in inventories		-519.61
Adjustments for decrease (increase) in trade receivables		-952.50
Adjustments for decrease (increase) in other current assets		20.46
Adjustments for increase (decrease) in trade payables		-161.18
Adjustments for increase (decrease) in other current liabilities		-79.78
Adjustments for provisions		33.09
Total adjustments for working capital		-1659.52
Total adjustments for reconcile profit (loss)		-1452.33
Net cash flows from (used in) operations		-533.15
Dividends received		0.00
Interest paid		0.00
Interest received		-77.97
Income taxes paid (refund)		225.01
Other inflows (outflows) of cash		0.00
Net cash flows from (used in) operating activities before extraordinary items		-836.13
Proceeds from extraordinary items		0.00
Payment for extraordinary items		0.00
Net cash flows from (used in) operating activities		-836.13
4 Cash flows from used in investing activities		
Cash flows from losing control of subsidiaries or other businesses		0.00
Cash flows used in obtaining control of subsidiaries or other businesses		0.00
Other cash receipts from sales of equity or debt instruments of other entities		0.00
Other cash payments to acquire equity or debt instruments of other entities		0.00
Other cash receipts from sales of interests in joint ventures		0.00
Other cash payments to acquire interests in joint ventures		0.00

Cash flow statement - indirect

Particulars	Year ended (dd-mm-yyyy)
Date of start of reporting period	01-04-2025
Date of end of reporting period	31-03-2026
Whether results are audited or unaudited	Audited
Nature of report standalone or consolidated	Standalone
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0.00
Proceeds from sales of property plant and equipment	0.00
Purchase of property plant and equipment	57.82
Proceeds from sales of intangible assets	0.00
Purchase of intangible assets	0.00
Cash advances and loans made to other parties	0.00
Cash receipts from repayment of advances and loans made to other parties	0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts	0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0.00
Dividends received	0.00
Interest received	57.76
Income taxes paid (refund)	0.00
Other inflows (outflows) of cash	4.93
Proceeds from government grants	0.00
Net cash flows from (used in) investing activities before extraordinary items	4.87
Proceeds from extraordinary items	0.00
Payment for extraordinary items	0.00
Net cash flows from (used in) investing activities	4.87
5 Cash flows from used in financing activities	
Proceeds from issuing shares	2700.29
Proceeds from issuing other equity instruments	0.00
Proceeds from issuing debentures notes bonds etc	0.00
Proceeds from borrowings	0.00
Repayments of borrowings	254.60
Dividends paid	0.00
Interest paid	0
Income taxes paid (refund)	0.00
Other inflows (outflows) of cash	-566.05
Net cash flows from (used in) financing activities before extraordinary items	1879.64
Proceeds from extraordinary items	0.00
Payment for extraordinary items	0.00
Net cash flows from (used in) financing activities	1879.64
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	1048.38
6 Effect of exchange rate changes on cash and cash equivalents	
Effect of exchange rate changes on cash and cash equivalents	0.00
Net increase (decrease) in cash and cash equivalents	1048.38
Cash and cash equivalents cash flow statement at beginning of period	554.65
Cash and cash equivalents cash flow statement at end of period	1603.03

Home

Validate

Amount in (Lakhs)

Statement of Asset and Liabilities		
Particulars		Year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2025
	Date of end of reporting period	31-03-2026
	Whether results are audited or unaudited	Audited
	Nature of report standalone or consolidated	Standalone
Equity and liabilities		
1	Shareholders' funds	
	Share capital	1417.28
	Reserves and surplus	4037.78
	Money received against share warrants	0.00
	Total shareholders' funds	5455.06
2	Share application money pending allotment	0.00
3	Deferred government grants	0.00
4	Minority interest	
5	Non-current liabilities	
	Long-term borrowings	0.00
	Deferred tax liabilities (net)	0.00
	Foreign currency monetary item translation difference liability account	0.00
	Other long-term liabilities	
1		
2	Provision for Gratuity	98.29
3		
4		
5		
	Details of other long-term liabilities	<input type="button" value="Add"/> <input type="button" value="Delete"/>
	Total of other long-term liabilities	98.29
	Long-term provisions	0.00
	Total non-current liabilities	98.29
6	Current liabilities	
	Short-term borrowings	1853.43
	Trade Payables	
	(A) Total outstanding dues of micro enterprises and small enterprises	70.06
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	118.40
	Total Trade payable	188.46
	Other current liabilities	
1	Other Current Liabilities	204.32
2		
3		
4		
5		
	Details of other current liabilities	<input type="button" value="Add"/> <input type="button" value="Delete"/>
	Total of other current liabilities	204.32
	Short-term provisions	142.10
	Total current liabilities	2388.31
	Total equity and liabilities	7941.66
Assets		
1	Non-current assets	

Statement of Asset and Liabilities		
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2025
Date of end of reporting period		31-03-2026
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Standalone
(i)	Property, Plant and Equipment and Intangible assets	
	Property, Plant and Equipment	16.94
	Producing properties	0.00
	Intangible assets	12.06
	Preproducing properties	0.00
	Property, Plant and Equipment capital work-in-progress	0.00
	Intangible assets under development or work-in-progress	39.74
	Total Property, Plant and Equipment and Intangible assets	68.74
(ii)	Non-current investments	0.00
(v)	Deferred tax assets (net)	46.97
(vi)	Foreign currency monetary item translation difference asset account	0.00
(vii)	Long-term loans and advances	31.21
	Other non-current assets	
1	Other Non Current Assets	133.53
2		
3		
4		
5		
	Details of other non-current assets	<input type="button" value="Add"/> <input type="button" value="Delete"/>
	Total of other non-current assets	133.53
	Total non-current assets	280.45
2	Current assets	
	Current investments	0.00
	Inventories	1975.04
	Trade receivables	3722.52
	Cash and cash equivalents	1616.90
	Bank balance other than cash and cash equivalents	7.43
	Short-term loans and advances	3.34
	Other current assets	
1	Other Current Assets	335.98
2		
3		
4		
5		
	Details of other current assets	<input type="button" value="Add"/> <input type="button" value="Delete"/>
	Total of other current assets	335.98
	Total current assets	7661.21
	Total assets	7941.66
	Disclosure of notes on assets and liabilities	<input type="button" value="Add Notes"/>

Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-10-2025	01-04-2025
Date of end of reporting period		31-03-2026	31-03-2026
Whether results are audited or unaudited		Audited	Audited
Nature of report standalone or consolidated		Standalone	Standalone
1	Segment Revenue		
	(net sale/income from each segment should be disclosed)		
1	Aesthetic Devices & Device Consumables	400.66	735.66
2	Aesthetic Products	3763.26	5960.75
3			
4			
5			
6			
7			
8			
9			
10			
11			
12			
13			
14			
15			
	Total segment revenue	4163.92	6696.41
	Less: Inter segment revenue		
	Revenue from operations	4163.92	6696.41

2	Segment Result		
	Profit (+) / Loss (-) before tax and interest from each segment		
1	Aesthetic Devices & Device Consumables	132.34	299.84
2	Aesthetic Products	2355.53	3576.06
3			
4			
5			
6			
7			
8			
9			
10			
11			
12			
13			
14			
15			
	Total Profit before tax	2487.87	3875.90
	i. Finance cost	75.54	179.61
	ii. Other unallocable expenditure net off unallocable income	1390.82	2777.11
	Profit before tax	1021.51	919.18

3	(Segment Asset - Segment Liabilities)		
	Segment Asset		
1	Aesthetic Devices & Device Consumables	1035.23	1035.23
2	Aesthetic Products	4662.33	4662.33
3			
4			
5			
6			
7			
8			
9			
10			

Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-10-2025	01-04-2025
Date of end of reporting period		31-03-2026	31-03-2026
Whether results are audited or unaudited		Audited	Audited
Nature of report standalone or consolidated		Standalone	Standalone
11			
12			
13			
14			
15			
Total Segment Assets		5697.56	5697.56
Un-allocable Assets		2244.11	2244.11
Net Segment Assets		7941.67	7941.67

4	Segment Liabilities		
	Segment Liabilities		
1	Aesthetic Devices & Device Consumables	0.00	0.00
2	Aesthetic Products	0.00	0.00
3			
4			
5			
6			
7			
8			
9			
10			
11			
12			
13			
14			
15			
Total Segment Liabilities		0.00	0.00
Un-allocable Liabilities		2486.60	2486.60
Net Segment Liabilities		2486.60	2486.60

Disclosure of notes on segments	Add Notes
--	---

Home

Validate

Details of Impact of Audit Qualification		
Whether results are audited or unaudited	Audited	
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion	
Auditor's opinion		
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results	Yes	
Audit firm's name	Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI	Certificate valid upto
<input type="button" value="Add"/> <input type="button" value="Delete"/>		
1	C.B.Mehta & Associates	Yes 31-07-2027

Home

Validate

Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary				
1	Aakaar Medical Technologies Limited	AALCA7587Q	Dilip Ramesh Meswani	AACHD0490B	Founder, Managing Director and Promoter	Remuneration		27.00	NA
2	Aakaar Medical Technologies Limited	AALCA7587Q	Dilip Ramesh Meswani	AACHD0490B	Founder, Managing Director and Promoter	Loan		250.00	NA
3	Aakaar Medical Technologies Limited	AALCA7587Q	Dilip Ramesh Meswani	AACHD0490B	Founder, Managing Director and Promoter	Any other transaction	Interest on loan	164.25	NA
4	Aakaar Medical Technologies Limited	AALCA7587Q	Bindi Dilip Meswani	AAEPM7338R	Chairperson and Promoter	Any other transaction	Consultation Fees	15.00	NA
5	Aakaar Medical Technologies Limited	AALCA7587Q	Bindi Dilip Meswani	AAEPM7338R	Chairperson and Promoter	Any other transaction	Rent	2.00	NA
6	Aakaar Medical Technologies Limited	AALCA7587Q	Milouni Dilip Meswani	BBOPM5111Q	Manager and Promoter Grp Member and daughter of MD	Remuneration		13.20	NA
7	Aakaar Medical Technologies Limited	AALCA7587Q	Rita Meswani	AJFPM7349J	Sister of MD and Promoter Grp Member	Remuneration		3.60	NA
8	Aakaar Medical Technologies Limited	AALCA7587Q	Abhash Dilip Meswani	BCMPM2345D	Son of Founder & MD and Promoter Grp Member	Any other transaction	Rent	12.55	NA
9	Aakaar Medical Technologies Limited	AALCA7587Q	Dr. Rahul Sawakhande	BFYPS7479K	C.E.O. & Director	Remuneration		99.96	NA
10	Aakaar Medical Technologies Limited	AALCA7587Q	Dr. Rahul Sawakhande	BFYPS7479K	C.E.O. & Director	Any other transaction	Loan given to CEO	41.95	NA
11	Aakaar Medical Technologies Limited	AALCA7587Q	Rajendra Dhandhukia	ADWPD1147Q	Independent Director	Remuneration		1.00	NA
12	Aakaar Medical Technologies Limited	AALCA7587Q	Deepanjan Perival	AKNPP6794P	Independent Director	Remuneration		1.00	NA
13	Aakaar Medical Technologies Limited	AALCA7587Q	Anoopkumar Pillai	ADCPP7239F	Company Secretary & Compliance Officer	Remuneration		12.00	NA
14	Aakaar Medical Technologies Limited	AALCA7587Q	Rakesh Parekh	AMYPP0706G	Chief Financial Officer	Remuneration		18.00	NA
15	Aakaar Medical Technologies Limited	AALCA7587Q	Aesthetic Solutions -HUF	AACHD0490B	Founder and MD is the Karta of HUF	Sale of goods or services		10.00	NA
16	Aakaar Medical Technologies Limited	AALCA7587Q	Rajendra Dhandhukia	ADWPD1147Q	Independent Director	Any other transaction	Professional Fees	0.25	NA
17	Aakaar Medical Technologies Limited	AALCA7587Q	Deepanjan Perival	AKNPP6794P	Independent Director	Any other transaction	Professional Fees	0.50	NA
18	Aakaar Medical Technologies Limited	AALCA7587Q	Bindi Dilip Meswani	AAEPM7338R	Chairperson and Promoter	Any other transaction	Interest on loan	3.69	NA
19	Aakaar Medical Technologies Limited	AALCA7587Q	Shweta Shah	BLYP52050L	Chief Financial Officer	Remuneration		13.48	NA
20	Aakaar Medical Technologies Limited	AALCA7587Q	Sharda Meswani	AJFPM7348K	Mother of Founder & MD and Promoter Grp Member	Any other transaction	Interest on loan	2.80	NA
21	Aakaar Medical Technologies Limited	AALCA7587Q	Shruti Mishra	BBWPM2742R	Consultant and Relative of MD and Chairman	Any other transaction	Consultation Fees	15.00	NA

Total value of transaction during the reporting period

Notes:

1. The details in this format are required to be provided for all transactions undertaken during the reporting period. However, opening and closing balances, including commitments, to be disclosed for existing related party transactions even if there is no new related party transaction during the reporting period.

2. Where a transaction is undertaken between members of the consolidated entity (between the listed entity and its subsidiary or between subsidiaries), it may be reported once.

3. Listed banks shall not be required to provide the disclosures with respect to related party transactions involving loans, inter-corporate deposits, advances or investments made or given by the listed banks.

4. For companies with financial year ending March 31, this information has to be provided for six months ended September 30 and six months ended March 31.

Companies with financial years ending in other months, the six months period shall apply accordingly.

5. Each type of related party transaction (for e.g. sale of goods/services, purchase of goods/services or whether it involves a loan, inter-corporate deposit, advance or investment) with a single party shall be disclosed separately and there should be no clubbing or netting of transactions of same type.

However, transactions with the same counterparty of the same type may be aggregated for the reporting period. For instance, sale transactions with the same party may be aggregated for the reporting period and purchase transactions may also be disclosed in a similar manner.

There should be no netting off for sale and purchase transactions. Similarly, loans advanced to and received from the same counterparty should be disclosed separately, without any netting off.

6. In case of a multi-year related party transaction:

a. The aggregate value of such related party transaction as approved by the audit committee shall be disclosed in the column "Value of the related party transaction as approved by the audit committee".

b. The value of the related party transaction ratified by the audit committee shall be disclosed in the column "Value of the related party transaction ratified by the audit committee".

c. The value of the related party transaction undertaken in the reporting period shall be reported in the column "Value of related party transaction during the reporting period".

7. "Cost" refers to the cost of borrowed funds for the listed entity. 8. Transactions such as acceptance of fixed deposits by banks/NBFCs, undertaken with related parties, at the terms uniformly applicable /offered to all shareholders/ public shall also be reported.

					Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments				
Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Nature (loan/ advance/ intercorporate deposit/ investment)
			Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	
27.00	14-06-2025	13.50	0.00	0.00					
250.00	25-02-2025	89.50	89.50	0.00					Loan
164.25	25-02-2025	3.50	0.00	0.00					
15.00	13-08-2025	7.50	0.00	0.00					
2.00	25-02-2025	12.60	0.00	0.00					
13.20	13-08-2025	6.60	0.00	0.00					
3.60	13-08-2025	1.80	0.00	0.00					
12.55	25-02-2025	6.55	0.00	0.00					
99.96	14-06-2025	49.98	0.00	0.00					
41.95	25-02-2025	1.39	35.95	34.55					Loan
1.00	25-02-2025	0.50	0.00	0.00					
1.00	25-02-2025	0.50	0.00	0.00					
12.00	25-02-2025	6.00	0.00	0.00					
18.00	15-12-2025	5.17	0.00	0.00					
10.00	25-02-2025	1.97	0.00	0.00					
0.25	25-02-2025	0.25	0.00	0.00					
0.50	25-02-2025	0.50	0.00	0.00					
3.69	25-02-2025	0.05	0.00	0.00					
13.48	25-02-2025	2.96	0.00	0.00					
2.80	25-02-2025	0.14	0.00	0.00					
15.00	12-02-2026	2.01	0.00	0.00					
		212.97							

ite deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

Details of the loans, inter-corporate deposits, advances or investments

Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	Notes
9.00%	5 years	Unsecured	Working Capital	Current year loan repayment done for 89.5 Lakhs

[Home](#)[Validate](#)

Amount in (Lakhs)

Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)	
Mode of Fund Raising	Public Issues
Description of mode of fund raising (Applicable in case of others is selected)	
Date of Raising Funds	27-06-2025
Amount Raised	2700.29
Report filed for Quarter ended	31-03-2026
Monitoring Agency	Not applicable
Monitoring Agency Name, if applicable	
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	
If Yes, Date of shareholder Approval	
Explanation for the Deviation / Variation	NA
Comments of the Audit Committee after review	No Comments
Comments of the auditors, if any	No Comments

Objects for which funds have been raised and where there has been a deviation, in the following table:

Sr.	Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
	Add	Delete					
1	Working Capital Requirement	No	2035.00	0.00	935.00	0.00	
2	General Corporate Purpose	No	329.00	0.00	0.63	0.00	
3	Issue Expenses with GST	No	336.29	0.00	336.29	0.00	

Deviation or variation could mean:

- (a) Deviation in the objects or purposes for which the funds have been raised or
- (b) Deviation in the amount of funds actually utilized as against what was originally disclosed or
- (c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc

Signatory Details

Name of signatory	Rakesh Parekh
Designation of person	Chief Financial Officer
Place	MUMBAI
Date	15-05-2026